TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02760862
Drug: hydrocortisone 100mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
Study: NCT00648700
Drug: Levothyroxine Sodium Tablets 300 μg
Normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2x300mcg, single dose fasting
Study: NCT00648700
Drug: Levothroid® Tablets 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x300mcg, single dose fasting
Study: NCT00549614
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, 250 mg, 4 times daily for 28 days
Study: NCT03463083
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension.
Study: NCT02072447
Drug: YH4808 PO and [14C]-YH4808 IV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01757808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo at a dose of 500mg for one month followed by a dose of 1000mg.
Study: NCT00498537
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01066572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo; identical tablets to Lisinopril.
Study: NCT00577629
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
Study: NCT00577629
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
Study: NCT01981616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion
Study: NCT00546130
Drug: Krestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
Study: NCT02759198
Drug: YH23537
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
Study: NCT02759198
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Celecoxib 200mg
Study: NCT02759198
Drug: YH23537 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
Study: NCT02373254
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg and 800 mg
Study: NCT02373254
Drug: Acetaminophen/hydrocodone
Normalized name: ACETAMINOPHEN/HYDROCODONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norco 5/325 mg and 10/325 mg
Study: NCT00437736
Drug: APO010
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
Study: NCT02867878
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01213238
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
Study: NCT02624310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01439152
Drug: BAY94-9343
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
Study: NCT01439152
Drug: BAY94-9343 (1.8 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Study: NCT01439152
Drug: BAY94-9343 (2.2 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Study: NCT01020123
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different doses of AZD1656 administered to 5 groups of patients
Study: NCT01020123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 placebo and glipizide placebo administered to 1 group of patients
Study: NCT01911741
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00004145
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03541603
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Study: NCT03343301
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.
Study: NCT02027220
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
Study: NCT03437668
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT04087096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered at postoperative months 1, 7, and 13
Study: NCT04087096
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
Study: NCT01058408
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once a day
Study: NCT04206579
Drug: 10% Dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mixture of 150 cc dextrose 10% in oral formulation
Study: NCT01800825
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
Study: NCT01800825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be an identical placebo comparator made of starch.
Study: NCT00049244
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00721799
Drug: 18F-Fluorothymidine PET scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
Study: NCT02673840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
Study: NCT02177500
Drug: Telmisartan + hydrochlorothiazide
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02177500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02629783
Drug: corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
Study: NCT02800811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
Study: NCT00770211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Study: NCT04155645
Drug: AZD8233 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
Study: NCT04155645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive SC dose of placebo injection.
Study: NCT03451370
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.~To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal.
Study: NCT00003957
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02301234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study: NCT02301234
Drug: Celecoxib 100 mg
Normalized name: celecoxib 100 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind capsules taken twice daily for up to 16 weeks.
Study: NCT02301234
Drug: Celecoxib 100 mg Matching Placebo
Normalized name: celecoxib 100 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind capsules taken twice daily for up to 16 weeks.
Study: NCT01966471
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study: NCT01966471
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Study: NCT02900027
Drug: APOC-III-L-Rx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
Study: NCT02002663
Drug: Methylprednisolone 1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02002663
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00471263
Drug: Casimax
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01384877
Drug: Placebo (D5W)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
Study: NCT01677286
Drug: Doxycycline 100 mg po bid x 12 months
Normalized name: doxycycline monohydrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg by mouth twice daily for 1 year.
Study: NCT00471263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00668616
Drug: Cyclophosphamide, Epirubicin, Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
Study: NCT05319275
Drug: Acetyllevocarnitine Hydrochloride Tablets
Normalized name: acetylcarnitine hydrochloride
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg (2×250 mg/tablet) after meal, 3 times per day
Study: NCT04202835
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post Transplant Cyclophosphamide
Study: NCT05319275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg (2×250 mg/tablet) after meal, 3 times per day
Study: NCT00301834
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02617537
Drug: EE20/DRSP(YAZ,BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
Study: NCT02617537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for 28 days per 28-day intake cycle
Study: NCT04100642
Drug: Hemay808
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical apply
Study: NCT04100642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical apply
Study: NCT00368160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00637923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
Study: NCT00601965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill of daily oral escitalopram
Study: NCT03634514
Drug: Recombinant human growth hormone - Hormotrop
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
Study: NCT01890161
Drug: AXP1275
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXP1275 50 mg (2 × 25-mg capsules)
Study: NCT01890161
Drug: AXP1275 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXP1275 matching placebo (2 capsules)
Study: NCT01893437
Drug: RO6799477
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of RO6799477
Study: NCT02292667
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
Study: NCT01202214
Drug: 1440115
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01202214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01839487
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
Study: NCT00190567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03019796
Drug: MEDICATION AND EXERCISE TRAINING
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE).
Study: NCT00436033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03427411
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
Study: NCT01516593
Drug: Induction Phase
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: * dd -2 to 1: Methylprednisolone~* dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~* dd 2, Rituximab~* dd 7, Methotrexate~* dd 14, Rituximab~* dd 15, Etoposide~* dd 21, Methotrexate~* dd 29, Rituximab and Doxorubicin~* dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~1. pts in CR: consolidation phase followed by bulky site irradiation~2. pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~3. pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation
Study: NCT01516593
Drug: Consolidation Phase (on day +50)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * dd 1-2: cytarabine twice a day~* dd 3 and 11: rituximab~* dd 11-13: leukapheresis for PBPC collection.
Study: NCT03212365
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 40 mg enoxaparin twice daily
Study: NCT04394624
Drug: SAR408701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion
Study: NCT00461565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Study: NCT00461565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Study: NCT01155999
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
Study: NCT00409773
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
Study: NCT00409773
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
Study: NCT00049231
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03697460
Drug: INCB018424
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
Study: NCT03170713
Drug: arveles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study: NCT03170713
Drug: intrafen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study: NCT01398241
Drug: RO5267683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses
Study: NCT01398241
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses
Study: NCT01938417
Drug: tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03773055
Drug: NPC-06
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive once a day for 7 days.
Study: NCT04058613
Drug: ALB Protein, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
Study: NCT04123392
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT00515320
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily oral dispersible tablet 2mg 9mg or 18mg
Study: NCT00117377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo application bid
Study: NCT00515320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dispersible tablet placebo
Study: NCT05787028
Drug: AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one AD16 tablet in the morning
Study: NCT05787028
Drug: AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take a placebo pill matching AD16 once in the morning
Study: NCT00321113
Drug: steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03408899
Drug: PC-1005 gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
Study: NCT01525953
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy according to standard